Patents by Inventor Joseph J. Romano

Joseph J. Romano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970480
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: April 30, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
  • Publication number: 20240083896
    Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 14, 2024
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Xiaoyang DONG, Mark Andrew ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, Joseph J. ROMANO, David Glenn WASHBURN
  • Publication number: 20230103791
    Abstract: The present invention relates to Nav1.8 Inhibitor 2,3-dihydroquinazolin compounds of Formula (X): wherein Y?, X?, B?, R1?, R2?, R3?, R5?, R6?, R7?, and z1 are as defined herein; or pharmaceutically acceptable salts or tautomer forms thereof, corresponding pharmaceutical compositions or formulations, methods or processes of compound preparation, methods, compounds for use in, uses for and/or combination therapies for treating pain and/or pain-related or associated disease(s), disorder(s) or condition(s), respectively.
    Type: Application
    Filed: June 23, 2020
    Publication date: April 6, 2023
    Inventors: Roderick S. DAVIS, Mark ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, William H. MILLER, Joseph J. ROMANO, Mythily VIMAL, Maben YING, David G. WASHBURN
  • Publication number: 20230071675
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: May 17, 2022
    Publication date: March 9, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
  • Patent number: 11377440
    Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: July 5, 2022
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: David T. Fosbenner, Todd L. Graybill, Jianxing Kang, Bryan W. King, Yunfeng Lan, Lara Kathryn Leister, Mukesh K. Mahajan, John F. Mehlmann, Angel I. Morales-Ramos, George Scott Pesiridis, Joshi M. Ramanjulu, Joseph J. Romano, Stuart Paul Romeril, Mark J. Schulz, Huiqiang Zhou, Junya Qu
  • Patent number: 11365190
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 21, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth Charnley, Gren Z. Wang, Joseph J. Romano
  • Publication number: 20210238172
    Abstract: The invention relates to combinations comprising a compound of the formula: or a salt thereof; and one or more additional pharmaceutically agents active against HIV, and methods of using the same.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 5, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael Gerard DARCY, Jason W. DODSON, Xiaoyang DONG, David FAVRE, Terry Vincent HUGHES, Jianxing KANG, Lara Kathryn LEISTER, Yuehu LI, Yiqian LIAN, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
  • Publication number: 20210139473
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 13, 2021
    Inventors: Adam Kenneth CHARNLEY, Gren Z. Wang, Joseph J. Romano
  • Patent number: 10981901
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 20, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Joseph J. Romano, Jianxing Kang
  • Publication number: 20200291001
    Abstract: Disclosed are compounds having the formula: (I) wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, R17, Rx, and Ry are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: October 4, 2018
    Publication date: September 17, 2020
    Inventors: David T. FOSBENNER, Todd L. GRAYBILL, Jianxing KANG, Bryan W. KING, Yunfeng LAN, Lara Kathryn LEISTER, Mukesh K. MAHAJAN, John F. MEHLMANN, Angel I. MORALES-RAMOS, George Scott PESIRIDIS, Joshi M. RAMANJULU, Joseph J. ROMANO, Stuart Paul ROMERIL, Mark J. SCHULZ, Huiqiang ZHOU, Junya QU
  • Patent number: 10220030
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 5, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam Kenneth Charnley, Pamela A. Haile, Robert W. Marquis, Jr., John F. Mehlmann, Joseph J. Romano, Robert R. Singhaus, Jr., Gren Z. Wang
  • Patent number: 10189820
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: January 29, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: John F. Mehlmann, Joseph J. Romano
  • Patent number: 9994529
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: June 12, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam K. Charnley, Michael P. Demartino, Xiaoyang Dong, Patrick M. Eidam, Pamela A. Haile, Robert W. Marquis, Jr., Joshi M. Ramanjulu, Joseph J. Romano, Ami Lakdawala Shah, Robert R. Singhaus, Jr., Gren Wang
  • Publication number: 20180105514
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: January 3, 2018
    Publication date: April 19, 2018
    Inventors: John F. MEHLMANN, Joseph J. ROMANO
  • Publication number: 20180085365
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: November 14, 2017
    Publication date: March 29, 2018
    Inventors: Michael Jonathan BURY, Linda N. CASILLAS, Adam Kenneth CHARNLEY, Pamela A. HAILE, Robert W. MARQUIS, JR., John F. MEHLMANN, Joseph J. ROMANO, Robert R. SINGHAUS, JR., Gren Z. WANG
  • Patent number: 9738661
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 22, 2017
    Assignees: MERCK SHARP & DOHME CORP., MSD ITALIA S.R.L.
    Inventors: Nigel J. Liverton, Vincenzo Summa, Steven Harper, John A. McCauley, Joseph J. Romano, Michael T. Rudd
  • Publication number: 20170152233
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 1, 2017
    Inventors: Michael Jonathan BURY, Linda N. CASILLAS, Adam K. CHARNLEY, Michael P. DEMARTINO, Xiaoyang DONG, Patrick M. EIDAM, Pamela A. HAILE, Robert W. MARQUIS, JR., Joshi M. RAMANJULU, Joseph J. ROMANO, Ami Lakdawala SHAH, Robert R. SINGHAUS, JR., Gren WANG
  • Publication number: 20170128437
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 11, 2017
    Inventors: Michael Jonathan BURY, Linda N. CASILLAS, Adam Kenneth CHARNLEY, Pamela A. HAILE, Robert W. MARQUIS, JR., John F. MEHLMANN, Joseph J. ROMANO, Robert R. SINGHAUS, JR., Gren Z. WANG
  • Patent number: 9604938
    Abstract: Disclosed are compounds having the formula (Formula I)): wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: March 28, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam K. Charnley, Michael P. Demartino, Xiaoyang Dong, Patrick M. Eidam, Pamela A. Haile, Robert W. Marquis, Jr., Joshi M. Ramanjulu, Joseph J. Romano, Ami Lakdawala Shah, Robert R. Singhaus, Jr., Gren Wang
  • Patent number: 9604963
    Abstract: Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: March 28, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Jonathan Bury, Linda N. Casillas, Adam Kenneth Charnley, Pamela A. Haile, Robert W. Marquis, Jr., John F. Mehlmann, Joseph J. Romano, Robert R. Singhaus, Jr., Gren Z. Wang